Adjuvant Treatment for HER2+ Early Breast Cancer Receives FDA Approval Officials with the FDA have approved ado-trastuzumab emtansine (Kadcyla, Genentech) for post-surgery treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab (Herceptin)-based treatment.
https://www.gene.com/media/press-releases/14785/2019-05-03/fda-approves-genentechs-kadcyla-for-adju
No comments:
Post a Comment